Take the Next Step

Enter your email address to stay informed with the latest information about portfolio monitoring

Magnifying Glass

Check for Losses!

Kaplan Fox has the experience, skills, and resources to aggressively pursue our clients' rights on issues of securities fraud.

Contact Us to Start

Current Case Investigations

OPKO Health, Inc.

September 11, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of OPKO Health, Inc. (“OPKO” or the “Company”) (Nasdaq: OPK).

USA Technologies, Inc.

September 11, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of USA Technologies, Inc. (“USA Technologies” or the “Company”), which is based in Malverne, Pennsylvania (Nasdaq: USAT).

Danske Bank A/S

September 11, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors of Danske Bank A/S American Depository Shares (“Danske” or the “Company”) (OTC: DNKEY) (CUSIP: 236363206).

CV Sciences, Inc.

September 6, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CV Sciences, Inc. (“CV Sciences” or the “Company”) (OTC: CVSI).  Investors who purchased CV Sciences common stock between June 19, 2017 and August 20, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the District of Nevada against CV Sciences and certain executives on behalf of investors that acquired CV Sciences common stock during the Class Period.

CBS Corporation

September 6, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of CBS Corporation (“CBS” or the “Company”) (NYSE: CBS).  Investors who purchased CBS securities between February 14, 2014 and July 27, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Southern District of New York against CBS and certain executives on behalf of investors that acquired CBS securities during the Class Period.

Nevro Corporation

September 6, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Nevro Corporation (“Nevro” or the “Company”) (NYSE: NVRO).  Investors who purchased Nevro common stock between January 8, 2018 and July 12, 2018 (the “Class Period”) may be affected.  A complaint has been filed in the United States District Court for the Northern District of California against Nevro and certain executives on behalf of investors that acquired Nevro common stock during the Class Period.

Load More

Settlement Filing Deadlines

Company Ticker Class Period Deadline Administrator
Xencor, Inc. XNCR On behalf of all former holders of Xencor, Inc.'s (the "Company") Series A-E preferred stock whose shares were converted to A-1 stock in the Recapitalization. 5/13/17 Strategic Claims Services  
Molycorp, Inc. MCP 2/21/2012 - 10/15/2013 5/18/17 Angeion Group  
Health Enhancement Products, Inc. (N/K/A Zivo Bioscience, Inc.) HEPI 10/31/2003 - 5/31/2004 5/18/17 Rust Consulting, Inc.  
Barclays Bank PLC (Electronic Foreign Exchange Trading - BARX) n/a 6/1/2008 - 4/21/2016 5/19/17 Garden City Group  
EZCORP, Inc. EZPW 4/19/2012 - 10/6/2014 5/19/17 Garden City Group  
King Digital Entertainment plc KING 3/26/2014 - 9/22/2014 5/23/17 Gilardi & Co.  
Load More